Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer

Most prostate cancer patients will progress to a castration-resistant state (CRPC) after androgen ablation therapy and despite the development of new potent anti-androgens, like enzalutamide (ENZ), which prolong survival in CRPC, ENZ-resistance (ENZ(R)) rapidly occurs. Re-activation of the androgen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sci Rep
Hauptverfasser: Thaper, Daksh, Vahid, Sepideh, Kaur, Ramandeep, Kumar, Sahil, Nouruzi, Shaghayegh, Bishop, Jennifer L., Johansson, Martin, Zoubeidi, Amina
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6251893/
https://ncbi.nlm.nih.gov/pubmed/30470788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-35612-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge